Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Carcinoid Tumor 1Adenocarcinoma, Follicular 1

Interventions

Capecitabine 6Temozolomide 5Octreotide 4Everolimus 4Leucovorin 3vatalanib 2pentetreotide 2Trastuzumab 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Fluorouracil 2Cisplatin 2Bortezomib 2Biological Therapy 2Bevacizumab 2veliparib 1tipifarnib 1romidepsin 1regorafenib 1pazopanib 1motesanib diphosphate 1gallium Ga 68 dotatate 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1aflibercept 1Thalidomide 1Streptozocin 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Somatostatinoma × aflibercept × Endocrine × Clear all
NCT02101918 2020-03-23

Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 10 charts
Endocrine

Somatostatinoma, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡